

Anti-CD19 [4G7]

Catalogue number: 153512

Sub-type: Primary antibody

Images:

Contributor

Inventor:

Institute: Clonogene LLC

Images:

Tool details

***FOR RESEARCH USE ONLY**

Name: Anti-CD19 [4G7]

Alternate name: B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12

Class: Monoclonal

Conjugate: Unconjugated

Description: CD19 assembles with the antigen receptor of B-lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 is a hallmark of B-cells, the protein has been used to diagnose cancers that arise from this type of cell - notably B-cell lymphomas. Since 2011 treatments targeting CD19 have begun to enter trials. Most current experimental anti-CD19 drugs in development work by exploiting the presence of CD19 to direct treatment specifically towards B-cell cancers. However, it is now emerging that the protein plays an active role in driving the growth of these cancers, most intriguingly by stabilizing the concentrations of the myc oncoprotein. This suggests that CD19 and its downstream signaling may be a more attractive therapeutic target than originally thought. CD19 has also been implicated in autoimmune diseases and may be a useful treatment target.

Purpose:

Parental cell:

Organism:

Tissue:

Model:

Gender:

Isotype: IgG1

Reactivity: Human

Selectivity:

Host:

Mouse

Immunogen: CD19

Immunogen UNIPROT ID:

Sequence:

Growth properties:

Production details:

Formulation:

Recommended controls:

Bacterial resistance:

Selectable markers:

Additional notes:

Target details

Target: CD19

Target alternate names:

Target background: CD19 assembles with the antigen receptor of B-lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 is a hallmark of B-cells, the protein has been used to diagnose cancers that arise from this type of cell - notably B-cell lymphomas. Since 2011 treatments targeting CD19 have begun to enter trials. Most current experimental anti-CD19 drugs in development work by exploiting the presence of CD19 to direct treatment specifically towards B-cell cancers. However, it is now emerging that the protein plays an active role in driving the growth of these cancers, most intriguingly by stabilizing the concentrations of the myc oncoprotein. This suggests that CD19 and its downstream signaling may be a more attractive therapeutic target than originally thought. CD19 has also been implicated in autoimmune diseases and may be a useful treatment target.

Molecular weight:

Ic50:

Applications

Application: ELISA ; FACS ; IHC ; WB

Application notes:

Handling

Format: Liquid

Concentration:

Passage number:

Growth medium:

Temperature:

Atmosphere:

Volume:

Storage medium:

Storage buffer:

Storage conditions:

Shipping conditions: Shipping at 4° C

Related tools

Related tools:

References

References:

CancerTools.org